Contents hide 1 About Encorafenib 2 Melanoma 3 Non-Small Cell Lung Cancer 4 Metastatic Colorectal Cancer About Encorafenib Encorafenib is a medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers. Melanoma Indicated in combination with binimetinib for unresectable or metastatic melanoma in patients with a BRAF V600E or V600K mutation, as detected by an FDA-approved test 450 mg PO qDay in combination with binimetinib Continue until disease progression or unacceptable toxicity See binimetinib drug monograph for recommended dosing information Non-Small Cell Lung Cancer … Continue reading BRATODX (Encorafenib)